|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Conference date: October 30, 2024 @ 5:30 AM Pacific Time
Biogen Should Resume Strong Growth with Zuranolone Approval [March 7, 2023 at Seeking Alpha]
Biogen: Beyond The Doom And Gloom [March 7, 2022 at Seeking Alpha]
Biogen's Case for Aduhelm [July 27, 2021 at Seeking Alpha]
Biogen 2021: Two Paths Diverge [February 8, 2021 at Seeking Alpha]
:
2024 |
|||
 |
|
|
|
| April 24, 2024 | Aug. 1, 2024 | Oct. 30, 2024 | |
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 |
2023 |
|||
|
|
|
|
| April 25, 2023 | July 25, 2023 | Nov. 8, 2023 | Feb. 13, 2024 |
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 |
2022 |
|||
|
|
|
|
| May 3, 2022 | July 20, 2022 | Oct. 25, 2022 | Feb. 15, 2023 |
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 |
2021 |
|||
|
|
|
|
| April 22, 2021 | July 22, 2021 | Oct. 20, 2021 | Feb. 3, 2022 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 |
2020 |
|||
|
|
|
|
| April 22, 2020 | July 22, 2020 | Oct. 21, 2020 | Feb. 3, 2021 |
| Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 |
2019 |
|||
|
|
|
|
| April 24, 2019 | July 23, 2019 | October 22, 2019 | January 30, 2020 |
| Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 |
2018 |
|||
|
|
|
|
April 24, 2018 |
July 24, 2018 |
October 23, 2018 |
January 29, 2019 |
Q1 2018 |
Q2 2018 |
Q3 2018 |
Q4 2018 |
2017 |
|||
|
|
|
|
April 25, 2017 |
July 25, 2017 |
October 24, 2017 |
January 25, 2018 |
Q1 2017 |
Q2 2017 |
Q3 2017 |
Q4 2018 |
2016 |
|||
|
|
|
|
04/21/2016 |
07/21/2016 |
10/26/2016 |
01/26/2017 |
Q1 2016 |
Q2 2016 |
Q3 2016 |
Q4 2016 |
2015 |
|||
|
|
|
|
04/24/2015 |
07/30/2015 |
10/21/2015 |
01/27/2016 |
Q1 2015 |
Q2 2015 |
Q3 2015 |
Q4 2015 |
2014 |
|||
|
|
|
|
04/23/2014 |
07/23/2014 |
10/22/2014 |
01/28/2015 |
Q1 |
Q2 |
Q3 |
Q4 |
2013 |
|||
|
|
|
|
04/25/2013 |
07/25/2013 |
10/28/2013 |
01/29/2014 |
Q1 |
Q2 |
Q3 |
Q4 |
2012 |
|||
|
|
|
|
05/01/2012 |
07/24/2012 |
10/25/2012 |
01/28/2013 |
Q1 |
Q2 |
Q3 |
Q4 |
2011 |
|||
|
|
|
|
04/21/2011 |
07/26/2011 |
10/28/2011 |
01/31/2012 |
Q1 |
Q2 |
Q3 |
Q4 |
2010 |
|||
|
|
|
|
04/20/2010 |
07/20/2010 |
10/26/2010 |
02/01/2011 |
Q1 |
Q2 |
Q3 |
Q4 |
2009 |
|||
|
|
|
|
04/16/2009 |
07/16/2009 |
10/20/2009 |
02/09/2010 |
Q1 |
Q2 |
Q3 |
Q4 |
2008 |
|||
|
|
|
|
04/23/2008 |
07/22/2008 |
10/21/2008 |
02/06/2009 |
Q1 |
Q2 |
Q3 |
Q4 |
2007 |
|||
|
|
|
|
02/06/2008 |
10/23/2007 |
07/24/2007 |
05/02/2007 |
Q4 |
Q3 |
Q2 |
Q1 |
2006 |
|||
|
|
|
|
02/15/2007 |
10/31/2006 |
07/26/2006 |
04/26/2006 |
Q4 |
Q3 |
Q2 |
Q1 |
Biogen Aducanumab Committee Danger and Opportunity [October 28, 2020 @ Seeking Alpha]
Biogen's Alzheimer's Therapy Submission In View [April 4, 2020 @ Seeking Alpha]
Biogen Is A Buy Regardless Of Aducanumab [November 6, 2019 @ Seeking Alpha]
Biogen Q2 Results Show Resilience [July 31, 2019 at Seeking Alpha]
Biogen 2019 Outlook [February 11, 2019 at Seeking Alpha]
Biogen Outlook For The 2020s November 30, 2018
Biogen's Ionis Deal is Brilliant [April 25, 2018 at Seeking Alpha]
Biogen's Key Variable: Its Neuroscience Pipeline [March 18, 2018 at Seeking Alpha]
Biogen Key Q1 2017 Insights [April 26, 2017 @ Seeking Alpha]
Bioverativ Should Have A Strong Launch [Jan. 10, 2017 @ Seeking Alpha]
Biogen Spinraza (nusinersen) positive interim analysis of Phase 3 later-onset Spinal Muscular Atrophy trial [Biogen 11/7/16 press release]
Biogen Keys to Value in 2017 and Beyond [June 2, 2016 at Seeking Alpha]
A Look At Biogen's 2016 Catalysts [January 12, 2016 at Seeking Alpha]
Biogen Intends to Spin-off Hemophilia Business [5/4/2016 Biogen press release]
Can Biogen Idec Take Wing With Tecfidera? [July 29, 2014]
Biogen Idec: Too High Too Fast? [April 29, 2013]
Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Biogen Idec: Q3 Clues to Value [November 2, 2011]
Biogen Idec: Is there More Value? [July 11, 2011]
Biogen Idec PML Test Approved in Europe, Changing Tysabri Outlook [March 15, 2011]
Biogen Idec Hemophilia Therapies [September 30, 2010]
Gilenya, Biogen Idec, and MS [September 22, 2010]
FDA February 5, 2010 Tysabri and PML letter
Biogen Research and Development Presentation notes [March 25, 2009]
Biogen Idec Growth Acceleration [October 27, 2008 blog]
Biogen Idec: Will it Recover? [September 1, 2008 blog]
Choosing a Biotech Stock 3: Biogen Idec [September 14, 2007 blog]
Rituxan and Zevalin, A Cautionary Tale [July 14, 2007 at New York Times, registration required]
Biogen Idec and Tysabri [May 6, 2007 blog]
First acquired in February 2008
Biogen is a biotechnology pharmaceutical company which markets Tecfidera, Spinraza, Avonex, Tysabri, aduhelm and other drugs.
Biogen Web site:
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. Before making or terminating an investment you should always verify any factual basis of your decision.
Copyright 2024 William P. Meyers